aKRAS G12D

aKRAS G12D is a preclinical-stage therapeutic candidate developed by Oblique Therapeutics for the treatment of KRAS-mutated cancers. The program specifically targets the KRAS G12D mutation, which is a prevalent driver in various solid tumors, including pancreatic, colorectal, and lung adenocarcinomas. Developed using Oblique's proprietary Abiprot platform—a technology designed to identify hidden, functionally relevant epitopes—aKRAS G12D is intended to selectively inhibit the mutant KRAS protein. While the company also explores dual-targeting small molecules (such as aKRAS G12D/G12V), the aKRAS G12D program represents a mutation-specific approach to precision oncology.